fusion NTRK dans les tumeurs des glandes salivaires — pratiquement 100% des carc...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BMA-NTRK-FUSION-SALIVARY |
|---|---|
| Type | Pertinence thérapeutique |
| État | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Maladies | DIS-SALIVARY |
| Sources | SRC-FDA-CDS-2026 |
Faits relatifs à l ' action en justice
| Biomarqueur | BIO-NTRK-FUSION |
|---|---|
| Variante | fusion NTRK1/2/3 (ETV6-NTRK3 définit le carcinome sécréteur analogue mammaire, MASC) |
| Maladie | DIS-SALIVARY |
| Niveau ESCAT | IA |
| Combinaisons recommandées | larotrectinib monotherapy, entrectinib monotherapy (preferred for CNS disease) |
| Résumé des faits | NTRK fusion in salivary gland tumors — virtually 100% of mammary analogue secretory carcinoma (MASC) carry ETV6-NTRK3. Larotrectinib (NAVIGATE / pooled phase 1/2, Drilon NEJM 2018 — ORR 75% across tumor types, salivary subset ORR ~85%) and entrectinib (STARTRK-2 / ALKA / STARTRK-NG) are FDA-approved tumor-agnostic for NTRK-fusion solid tumors. Salivary MASC has among the highest response rates. |
Notes
ESCAT IA. OncoKB Level 1. MASC re-classified from acinic cell carcinoma in 2010 — driven entirely by ETV6-NTRK3 fusion. Detection: pan-TRK IHC screen → confirm by FISH or NGS. Resistance: solvent-front (NTRK G595R / G623R) and gatekeeper (G667C) mutations → next-gen TRK inhibitor selitrectinib / repotrectinib in trials. Source-gap: SRC-NCCN-HEAD-AND-NECK / SRC-NAVIGATE-DRILON-2018 / SRC-STARTRK2-DRILON-2020 not yet ingested.
Utilisé par
No reverse references found in the YAML corpus.